Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dishman Carbogen...

    Dishman Carbogen shares rise by 9 pc after I-T department conducts search at offices

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-26T16:29:57+05:30  |  Updated On 26 Dec 2019 4:29 PM IST

    Ahmedabad: The share price of Dishman Carbogen Amcis rose by over 9 per cent on Thursday after officials of the Income Tax Department conducted search at the company's offices and manufacturing sites here.


    The Swiss company provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries.


    In a communication to stock exchanges, Dishman Carbogen said officials of the Income Tax Department conducted search at the company's offices and manufacturing sites from December 19 to 25.


    "The company extended full cooperation to officials during the search and provided all the information sought. We at Dishman Carbogen Amcis Ltd follow the highest standards of corporate governance and financial discipline," it said.


    "Our systems and processes are benchmarked by competent auditing and accounting standards, our dealings with our partners, investors, financial institutions and our clients are transparent and of the highest industry standards," it added.


    Read Also: Cipla shares jump 2 pc post agreement with CitiHealth Imports


    Dishman Carbogen's capabilities span from contract chemical process research and development to the supply of active pharmaceutical ingredients as well as drug products for pre-clinical studies, clinical trials and commercial use.


    Read Also: Unichem Lab shares jump over 7 pc after USFDA nod for Atenolol tablets

    active pharmaceutical ingredientsclinical trialsDishman Carbogen AmcisIncome Tax Departmentpharmaceutical and biopharmaceutical industries
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok